应用芳基锂合成查尔酮

苯基锂、2-甲氧基苯基锂和2,4-二甲氧基苯基锂分别与肉桂酸反应以相当好的收率生成相应的查尔酮;2,6-二甲氧基苯基锂与肉桂酸不发生反应,但能与肉桂酸甲酯反应生成2',6'-二甲氧基查尔酮;类似的还制得了2',4',6'-三甲氧基查尔酮和2',4',4,6'-四甲氧基查尔酮.2,4-二甲氧基苯基锂和2,4,6-三甲氧基苯基锂也能与γ-丁酸内酯反应分别生成γ-羟丙基-(2,4-二甲氧基苯基)酮和γ-羟丙基-(2,4,6-三甲氧基苯基)酮.没发现三级醇生成.     

含氟苯并异噁唑衍生物的合成及活性研究

以2,4-二甲氧基苯胺为起始原料,通过乙酰化保护合成N-(2,4-二甲氧基苯基)乙酰胺(2),经傅克反应合成N-(4-羟基-2-甲氧基-5-丙酰基苯基)乙酰胺(3),3再与盐酸羟胺反应生成N-(4-羟基-5-(1-(羟基亚氨基)丙基)-2-甲氧基苯基)乙酰胺(4),4在DMF-DMA作用下生成N-(3-乙基-6-甲氧基...     

4-对羟基苯基-2-丁酮的合成

以生物质来源的对甲氧基苯甲醛(大茴香醛)为原料,经还原反应制备得到对甲氧基苄醇,经氯代反应制备得到对甲氧基氯苄,再与乙酰乙酸乙酯经取代反应制备得到2-乙酰基-3-(4-甲氧基苯基)丙酸乙酯,再经串联的水解、脱羧反应制备得到4-(4-甲氧基苯基)-2-丁酮,最后经脱甲基反应制备得到4-对羟基苯基-2-丁酮,总收率为60.7%。具有路线简捷、易于操作、环境友好、收率高等优点。     

5-[2-(对苯偶氮苯氧基)丁氧基]苯基-10,15,20-三[(对甲氧基苯基)]卟啉及其金属配合物的合成

以5-[2-(4-溴丁氧基)苯基]-10,15,20-三(对甲氧基苯基)卟啉和对羟基偶氮苯为原料,经取代反应合成新化合物5-[2-(对苯偶氮苯氧基)丁氧基]苯基-10,15,20-三[(对甲氧基苯基)]卟啉(2),2经配位反应合成了金属铜,锌配合物(2a)和(2b),其结构经UV-Vis,1H NMR,IR和元素分析表征。     

天然产物Combretastatin A-1和Combretastatin B-1的合成

基于Perkin反应策略合成了具有强效抗肿瘤、抗血管活性的天然产物Combretastatin A-1(CA1)和Combretastatin B-1(CB1).以2,3,4-三羟基苯甲醛(1)为起始物, 经单甲基化反应得到2,3-二羟基-4-甲氧基苯甲醛(2), 再经酚羟基保护得到2,3-二异丙基-4-甲氧基苯甲醛(3), 该化合物与3,4,5-三甲氧基苯乙酸(4)发生Perkin反应分离得到E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二异丙氧基-4'-甲氧基)丙烯酸(E-5), 经脱羧反应得到Z-3,4,4',5-四甲氧基-2',3'-二异丙氧基二苯乙烯(6), 最后经脱保护反应得到CA1.另外, 将E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二异丙氧基-4'-甲氧基)丙烯酸(E-5)脱去保护基得到E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二羟基-4'-甲氧基)丙烯酸(7), 该化合物经脱羧-异构化反应得到E-3,4,4',5-四甲氧基-2',3'-二羟基二苯乙烯(E-CA1), 最后经催化氢化得到CB1.     

三苯甲基衍生物的合成

以二苯基(对甲氧基)苯基氯甲烷和溴乙酸乙酯反应得到3,3-二苯基-3-(对甲氧基)苯基丙酸乙酯,然后水解和酰氯化得到3,3-二苯基-3-(对甲氧基)苯基丙酰氯,再用LiAlH4还原得到其醇,再氧化得到3,3-二苯基-3-(对甲氧基)苯基丙醛。     

取代苯基烷基酮与叔丁基氯化镁反应的机理研究

通过EPR技术观察到一系列典型的烷基或甲氧基取代的苯基烷基酮ArCOR(Ar=2,5-二甲基苯基(1);2,5-二甲氧基苯基(2);4-叔丁基-2,5-二甲氧基苯基(3))与t-BuMgCl反应中形成的自由基阴离子中间体[ArC(R)OMgCl]。产物分析表明,反应主要生成还原产物[ArCH(R)OH]和1,2-加成产物[ArC(R)(t-Bu)OH]。降低溶剂极性及反应温度都有利于还原产物的生成。对上述反应的可能历程作了简单讨论。     

新型手性双功能有机催化剂的合成及其催化不对称Henry反应合成(R)-aegeline

以(S)-2-氨甲基-1-乙基吡咯烷为原料,合成了新型手性双功能有机催化剂(S)-1-[3,5-二(三氟甲基)苯基]-3-(1-乙基吡咯烷基-2-甲基)硫脲(2,产率82.2%).用2催化对甲氧基苯甲醛与硝基甲烷的不对称Henry反应,制得(R)-1-(4-甲氧基苯基)-2-硝基乙醇(3, 84%ee);3经Pd/C催化氢化得到(R)-2-氨基-1-(4-甲氧基苯基)乙醇(4);4与反式肉桂酰氯反应合成了(R)-aegeline,总产率37.6%(以对甲氧基苯甲醛计).化合物的结构经1H NMR, 13C NMR和MS表征.     

2-取代吲哚的染料敏化光氧化反应

2-苯基吲哚 (1a) 在甲醇中的染料敏化光氧化反应给出2-苯基-2-(2'-苯基-3'-吲哚基)二氢吲哚-3-酮 (2a) 和2-甲氧基-2-苯基二氢吲哚-3-酮 (4a), 相应N-甲基取代产物由1-甲基-2-苯基吲哚 (1b) 的类似反应获得。发现反应产物分布随吲哚 (1) 的浓度和介质酸度的变化而变化。对反应机理进行了推测, 其中当1a的反应在乙腈中进行时, 分离到了相应的反应中间体: 2-苯基-3H-吲哚-3-酮 (3a)。     

2,4,6-三甲基氧苯乙酮苯腙的成环反应

为了研究吲哚衍生物的生理活性与结构之间的关系, 我们采用 Fischer反应取代苯乙酮的苯腙与多聚磷酸(PPA)一起加热, 合成了一系列2-芳基吲哚。我们发现: 当取代苯乙酮分子中的芳基分别为2,3,4-三甲氧基苯基, 3,4,5-三甲氧基苯基或4,6-二甲基-2-甲氧基苯基时, 可以顺利地得到相应的2-芳基吲哚, 当芳基为2,4,6-三-甲氧基苯基时, 主要产物为4,6-二甲氧基-3-甲基-1-苯基吲唑。本文讨论了反应机理。     

氘代AZD9291的合成

吲哚和2,4-二氯嘧啶经偶联反应制得3-(2-氯嘧啶-4-基)-1H-吲哚(1); 1与CD₃I 经取代反应制得3-(2-氯嘧啶-4-基)-1-(甲基-d₃)-吲哚(2); 2经两步亲核取代反应制得N′-(2-二甲基氨基乙基)-2-甲氧基-N′-甲基-N-{［4-(1-(甲基-d₃)吲哚-3-基)］嘧啶-2-基}-5-硝基苯-1,4-二胺(4); 4经还原反应后,与氯丙酰氯发生缩合反应合成了氘代AZD9291,总收率8.5%,其结构经¹H NMR, ¹³C NMR和ESI-MS表征。     

新型P,N配体及基1,4-共轭加成反应

以2-萘酚为起始原料,经过氧化偶联,消旋体的拆分得到手性骨架2-氨基-2'-羟基-1,1'-联萘(NOBIN),并以S-NOBIN为原料,经过六步反应合成了两个新型配体S-(+)-2-(2-吡啶酰胺基)-2'-二苯基膦基-1,1'-联萘(1a)和S-(+)-2-(6-甲基-2-吡啶酰胺基)-2'-二苯基膦基-1,1'-联萘(1b)。并进行了铜配合物催化的二乙基锌对2-环己烯酮的1,4-共轭加成反应的研究。反应产物3-乙基环己酮(13)的e.e.值高达92%。     

合成SGLT2抑制剂埃格列净的新方法

以D-(+)-葡萄糖酸内酯为原料,经三甲硅基保护羟基后与5-溴-2-氯-4′-乙氧基二苯甲烷偶联制得(2S,3R,4S,5S,6R)-2-［4-氯-3-(4-乙氧苄基)苯基］-6-(羟甲基)-2-甲氧基四氢-2H-吡喃-3,4,5-三醇（2）; 2经羟基保护、氧化和羟醛缩合等5步反应制得(3S,4S,5R,6S)-3,4,5-三(苄氧基)-6-［4-氯-3-(4-乙氧苄基)苯基］-2-(羟甲基)-6-甲氧基四氢-2H-吡喃-2-甲醛（7）; 7经还原、脱苄同时关环制得埃格列净(1S,2S,3S,4R,5S)-5-［4-氯-3-(4-乙氧苄基)苯基］-1-(羟甲基)-6,8-二氧杂二环［3.2.1］辛烷-2,3,4-三醇,其结构经¹H NMR和LC-MS表征。     

带有四个不同芳基的环丁烷的合成、结构及光化学性质

通过不同杂芳基乙烯分子间的交叉光二聚反应在硫酸溶液中和中压汞灯照射下,合成了4种含7个不同取代芳基的环丁烷衍生物.用紫外和红外光谱及¹H和¹³CNMR谱确定其结构为顺式头尾相对型二聚体.     

Lipase-catalyzed resolution of (2R*,3S*)- and (2R*,3R*)-3-methyl-3-phenyl-2-aziridinemethanol at low temperatures and determination of the absolute configurations of the four stereoisomers

[reaction: see text] Lipase-catalyzed resolution of (2R*,3S*)-3-methyl-3-phenyl-2-aziridinemethanol, (+/-)-2, at low temperatures gave synthetically useful (2R,3S)-2 and its acetate (2S,3R)-2a with (2S)-selectivity (E = 55 at -40 degrees C), while a similar reaction of (2R*,3R*)-3-methyl-3-phenyl-2-aziridinemethanol, (+/-)-3, gave (2S,3S)-3 and its acetate (2R,3R)-3a with (2R)-selectivity (E = 73 at -20 degrees C). Compound (+/-)-2 was prepared conveniently via diastereoselective addition of MeMgBr to tert-butyl 3-phenyl-2H-azirine-2-carboxylate, (+/-)-1a, which was successfully prepared by the Neber reaction of oxime tosylate of tert-butyl benzoyl acetate 7a. The tert-butyl ester was requisite to promote this reaction. For determination of the absolute configuration of (2S,3R)-2a, enantiopure (2S,3R)-2 was independently prepared in three steps involving diastereoselective methylation of 3-phenyl-2H-azirine-2-methanol, (S)-10, with MeMgBr. The absolute configuration of (2S,3S)-3 was determined by X-ray analysis of the corresponding N-(S)-2-(6-methoxy-2-naphthyl)propanoyl derivative (S,S,S)-13.     

Evaluation of luminol-H(2)O(2)-KIO(4) chemiluminescence system and its application to hydrogen peroxide, glucose and ascorbic acid assays

A novel chemiluminescence (CL) system was evaluated for the determination of hydrogen peroxide, glucose and ascorbic acid based on hydrogen peroxide, which has a catalytic-cooxidative effect on the oxidation of luminol by KIO(4). Hydrogen peroxide can be directly determined by luminol-KIO(4)-H(2)O(2) CL system. The detection limit was 3.0x10(-8) mol l(-1) and the calibration graph was linear over the range of 2.0x10(-7)-6.0x10(-4) mol l(-1). The relative standard deviation of H(2)O(2) was 1.1% for 2.0x10(-6) mol l(-1) (N=11). Glucose was indirectly determined through measuring the H(2)O(2) generated by the oxidation of glucose in the presence of glucose oxidase at pH 7.6. The present method provides a source for H(2)O(2), which, in turn, coupled with the luminol-KIO(4)-H(2)O(2) CL reaction system. The CL was linearly correlated with glucose concentration of 0.6-110 mug ml(-1). The relative standard deviation was 2.1% for 10 mug ml(-1) (N=11). Detection limit of glucose was 0.08 mug ml(-1). Ascorbic acid was also indirectly determined by the suppression of luminol-KIO(4)-H(2)O(2) CL system. The calibration curve was linear over the range of 1.0x10(-7)-1.0x10(-5) mol l(-1) of ascorbic acid. The relative standard deviation was 1.0% for 8.0x10(-7) mol l(-1) (N=11). Detection limit of ascorbic acid was 6.0x10(-8) mol l(-1). These proposed methods have been applied to determine glucose, ascorbic acid in tablets and injection.     

Synthesis and Alkylation of 4-(2-Chlorophenyl)-3-cyano-6-hydroxy-5-(2-thienoyl)-6-trifluoromethylpiperidin-2-thione

4-(2-Chlorophenyl)-3-cyano-6-hydroxy-5-(2-thienoyl)-6-trifluoromethylpiperidin-2-thione, which was used for the synthesis of 2-allylthio-4-(2-chlorophenyl)-3-cyano-6-hydroxy-5-(2-thienoyl)-6-trifluoromethyl-1,4,5,6-tetrahydropyridine, was obtained by the reaction of 2-thienoyltrifluoroacetone with 2-chlorophenylphenylmethylenecyanothioacetamide or with a mixture of 2-chlorobenzaldehyde and cyanothioacetamide in the presence of N-methylmorpholine. The molecular and crystal structure of the piperidinthione have been established by X-ray crystallography.     

Enantiomeric separation of novel anticancer agent 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en-1-one

The enantiomers of 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en-1-one, a novel anticancer agent, were separated by derivatisation with caronaldehyde, separation of the resulting diastereoisomers of the corresponding esters by silica gel column chromatography and regeneration of alcohols (S)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en-1-one and (R)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en-1-one under aqueous conditions. The absolute configuration of the enantiomers was determined by 1H NMR studies of the corresponding Mosher esters. Alternatively, the enantiomers were separated by preparative HPLC to collect the (S)- and (R)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en-1-ones with high purity which was comparable with that obtained by the chemical method. The details of these methods have been presented herein.     

新型邻菲啰啉衍生物的合成

以2-［2-（2-甲氧基乙氧基）乙氧基］乙基-4-甲基苯磺酸为原料,经2步反应制得中间体2,2′-【2,5-二｛2-［2-（2-甲氧基乙氧基）乙氧基］｝1,4-二（4,4,5,5-四甲基）-1,3,2-二氧硼基】苯（6）; 3-溴-1,10-邻菲啰啉和6经Suzuki偶联反应合成了一个新型的邻菲啰啉衍生物--3,3′-【2,5-二｛2-［2-（2-甲氧基乙氧基）乙氧基］｝-1,4-二（1,10-菲啰啉基）】苯,其结构经¹H NMR和MALDI-TOF-MS表征。     

The practical synthesis of (2S)-7-methoxy-1,2,3,4-tetrahydro-2-naphthylamine via optical resolution of 2-(3-methoxybenzyl)succinic acid

We describe the practical synthetic route for (2S)-7-methoxy-1,2,3,4-tetrahydro-2-naphthylamine 1(2S)-2-amino-7-methoxytetraline; (S)-AMT]. (2R)-2-(3-Methoxybenzyl)succinic acid [(R)-1] was obtained by the optical resolution of 2-(3-methoxybenzyl)succinic acid (1) as the salt of (1R,2S)-2-(benzylamino)cyclohexylmethanol (7), and (R)-1 was converted to the optically active (2S)-7-methoxy-1,2,3,4-tetrahydro-2-naphthoic acid [(S)-2] by the intramolecular Friedel-Crafts reaction followed by catalytic hydrogenation. (S)-AMT was obtained from the acid (S)-2 by Hofmann rearrangement without racemization.